content_copy Vitro Biopharma Announces MaloneBailey L.L.P. As Its New Auditors

Vitro Biopharma Announces MaloneBailey L.L.P. As Its New Auditors

August 20, 2021

Vitro Biopharma Announces MaloneBailey L.L.P. As Its New Auditors

Vitro Biopharma Announces MaloneBailey L.L.P. As Its New Auditors

Golden, Colorado-July20th, 2020-Vitro Diagnostics, Inc. (OTCQB: VODG), dba Vitro Biopharma, announced that it has engaged MaloneBailey L.L.P. (Certified Public Accounting Firm ) as its new auditors that will be auditing the company’s consolidated balance sheets as of October 31, 2019 and October 31, 2020, and the related consolidated statements of income, changes in stockholders’ equity, and cash flows for the years then ended, and the related notes to the consolidated financial statements, all of which are to be included in the report (Form 10) proposed to be filed by the Company under the Securities Exchange Act of 1934 around December of 2020.

Founded in 1982, MaloneBailey is a full-service public accounting firm headquartered in Houston. MaloneBailey provides audit, tax, and consulting services to public and private companies. MaloneBailey is in exclusive company as one of only twelve CPA firms in the world that requires an annual inspection by the PCAOB; all other firms are inspected every three years. The Sarbanes-Oxley Act requires the PCAOB to conduct annual inspections for firms that regularly provide audit reports for more than 100 issuers.

MaloneBailey L.L.P

The data in the table above are available on the PCAOB

John R. Evans C.F.O. said “This is a next step forward for the company as it expands its investor base and grows its business in the public marketplace. The company has provided consistent quarterly and year-end financial results of operations over the last two-plus years which the company has filed as 8-K’s with the SEC and published on its website. Those disclosures were not audited as the company at that time did not have the financial resources to dedicate to those efforts. Now after the company has grown over the last two years the board of directors has approved the company to become fully reporting with a target going effective date of January 2021.”
Dr. James Musick said, “We are pleased to have John lead this effort forward as he has broad experience in public companies and the public capital markets that will benefit the company as it continues to grow its AlloRx Stem Cell™ business worldwide.”

Forward-Looking Statements

Statements herein regarding financial performance have not yet been reported to the SEC nor reviewed by the Company’s auditors. Certain statements contained herein and subsequent statements made by and on behalf of the Company, whether oral or written may contain “forward-looking statements”. Such forward-looking statements are identified by words such as “intends,” “anticipates,” “believes,” “expects” and “hopes” and include, without limitation, statements regarding the Company’s plan of business operations, product research, and development activities, potential contractual arrangements, receipt of working capital, anticipated revenues and related expenditures. Factors that could cause actual results to differ materially include, among others, acceptability of the Company’s products in the market place, general economic conditions, receipt of additional working capital, the overall state of the biotechnology industry, and other factors set forth in the Company’s filings with the Securities and Exchange Commission. Most of these factors are outside the control of the Company. Investors are cautioned not to put undue reliance on forward-looking statements. Except as otherwise required by applicable securities statutes or regulations, the Company disclaims any intent or obligation to update publicly these forward-looking statements, whether as a result of new information, future events, or otherwise.


Dr. James Musick
Chief Executive Officer
Vitro BioPharma
(303) 999-2130 Ext. 1
Source: Vitro Diagnostics, Inc.

Also in News

Pitt Hopkins FDA Trial
Vitro Biopharma Receives FDA Authorization to Conduct a Clinical Trial Using AlloRx Stem Cells® to Treat Pitt Hopkins Syndrome, a rare form of Autism

November 18, 2021 0 Comments

Golden, Colorado-November 9, 2021- Vitro Biopharma, Inc. announced receipt of FDA authorization and clearance to enroll patients in its IND for a phase I-II, randomized, double-blind, placebo-controlled study of the safety and efficacy of therapeutic treatment with AlloRx Stem Cells® in children with Pitt Hopkins Syndrome (PTHS), a rare neurogenetic disorder that features autistic traits. PTHS results from genetic mutations/deletions of a key brain development gene, TCF4 (transcription factor 4) that controls neurogenesis. 

Read More

Fitore and Infinivive logo
Vitro Biopharma Acquires Fitore Nutrition and Infinivive MD, Adding Revenues from Innovative Stem Cell Activation Products and Topical Cosmetic Stem Cell Serums

August 31, 2021 0 Comments

Golden, Colorado-August 31, 2021- Vitro Biopharma, Inc. ("Vitro') announced the acquisition of Fitore Nutrition ("Fitore") and Infinivive MD ("Infinivive"). Fitore, a private company headquartered in Denver, Colorado creates clinically validated supplements and sells them direct to consumers (D2C) via their unique digital marketing platform and SEO expertise.

Infinivive, located in Cherry Creek, Colorado developed the world's first topical cosmetic stem cell serum and is a nationally recognized company led by one of the top industry pioneers in the area of cosmetic surgery, Dr. Jack Zamora M.D.

Read More

Vitro Biopharma Signs Multi-Million Dollar Operating Service Contract with European Wellness Biomedical Group
Vitro Biopharma Signs Multi-Million Dollar Operating Service Contract with European Wellness Biomedical Group

August 20, 2021 0 Comments

Golden, Colorado-August 19, 2021-Vitro Biopharma, Inc. announced the signing of a contract with European Wellness Biomedical Group headquartered in Kuala Lumpur, Malaysia and it’s start-up subsidiary BioPep being registered in Delaware, USA to develop FDA-approval of biological products derived from existing mitochondrial peptide extracts now used globally as treatment of various conditions including aesthetic dermatology and skin revitalization, autism spectrum disorders, cardiovascular, metabolic and degenerative disorders, CKD and fertility through its global network of 12 (twelve) biomedical regenerative centers located throughout Europe and Asia Pacific. 

Read More